Summary:
There is no currently-approved pharmacotherapy for patients with Severe Bipolar Depression and Suicidal Ideation or behavior. The purpose of this phase 2b/3 trial is to determine whether patients with Severe Bipolar Depression and subacute Suicidal Ideation or Behavior (i.e. those not requiring inpatient care) can be treated effectively with NRX101.
Qualified Participants Must:
• 18 to 65 years of age
•
Confirmed active suicidal ideation
Qualified Participants May Receive:
Compensation for time and travel upon qualified entry into the study